Inclusion criteria: - Patients with a diagnosis of advanced, measurable or non-measurable, non-hematological cancer who have varying degrees of hepatic impairment. The cancer must be one that is either refractory to standard therapy or for which no standard therapy exists. Exclusion criteria: - Eastern Cooperative Oncology Group (ECOG) performance status (PS) >2 - Life expectancy <3 months - Need for a major surgical procedure or radiation therapy during the study - Evidence of another active malignancy - Prior chemotherapy, other investigational drug, biological therapy, targeted non-cytotoxic therapy and radiotherapy within 3 weeks prior to registration - Patients with known history of Gilbert's syndrome - Prior treatment with Cabazitaxel and a history of severe (Grade ≥3) hypersensitivity to taxanes, polysorbate-80, or to compounds with similar chemical structures The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.